CHIEH-KAI CHANTAI-SHUAN LAIVIN-CENT WU2021-11-302021-11-3020170263-6352https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033797273&doi=10.1097%2fHJH.0000000000001549&partnerID=40&md5=678056f6546feab3dd248131eca8661chttps://scholars.lib.ntu.edu.tw/handle/123456789/588420[SDGs]SDG3adipocytokine; aldosterone; glucocorticoid; glucocorticoid receptor; hydrocortisone; mineralocorticoid antagonist; mineralocorticoid receptor; tissue inhibitor of metalloproteinase 1; hydrocortisone; adipocyte; adrenalectomy; cohort analysis; drug efficacy; heart fibroblast; hormone release; human; hydrocortisone blood level; Letter; long term care; metabolic syndrome X; osteoporosis; prevalence; primary hyperaldosteronism; priority journal; protein binding; protein expression; quality of life; risk factor; Cushing syndrome; diabetes mellitus; hyperaldosteronism; risk; Cushing Syndrome; Diabetes Mellitus; Humans; Hydrocortisone; Hyperaldosteronism; Riskletter10.1097/HJH.0000000000001549290952332-s2.0-85033797273